INVESTOR PRESENTATION Summer/Fall 2024
THE DIGITAL PLATFORM
FOR DOCTORS
Leading Network Blue Chip Clients
Growth and Profit
5:47
The Lancet Respiratory Medicine
80%+ 20/20 22%
of all U.S.
Physicians¹
Top Hospitals
and Health Systems
Top Pharmaceutical
Manufacturers³
Subscription
Revenue Growth5
A
Atypical Presentation of COVID-19 in a 34 Year-
Old Man
22min read CME
The pandemic of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) challenges
>525K 118% 45%
Workflow Unique
Active Providers²
Net Revenue
Retention Rate4
Adj. EBITDA
Margin
doximity
1. As of 6/30/23.
2. For fiscal quarter ending 6/30/23.
3. Top 20 Pharmaceutical Manufacturers based on data from Evaluate, Top 20 hospitals based on U.S. News & World Report's Best Hospitals U.S. News Best Hospitals 2023-2024 Honor Roll.
4. For the trailing twelve month (TTM) period ending 6/30/23. Refer to appendix for the definition of Net Revenue Retention.
5. For the trailing twelve month (TTM) period ending 6/30/23.
6. For the trailing twelve month (TTM) period ending 6/30/23. Refer to appendix for the definition and non-GAAP reconciliation of Adjusted EBITDA and Adjusted EBITDA Margin.
61
15 Comments
more
迪
Natalia Birgisson, MD
Resident Physician
I was struck by the multiple possible etiologies
explaining his course, and what a reminder more
34-Reply
Add a comment
Anupam Jena, MD
your colleague was published 1d
Incremental Health Care Burden of
Treatment-Resistant Depression Among
Commercial, Medicaid, and Medicare...
Psychiatric services (Washington, DC.)
Home
Search
Dialer
fa
Residency
Proprietary
3View entire presentation